Head to Head Survey: Sophiris Bio (SPHS) versus Apricus Biosciences (APRI)

Sophiris Bio (NASDAQ: SPHS) and Apricus Biosciences (NASDAQ:APRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Valuation and Earnings

This table compares Sophiris Bio and Apricus Biosciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sophiris Bio N/A N/A -$11.16 million ($0.18) -12.39
Apricus Biosciences $5.76 million 6.13 -$7.43 million $0.58 4.00

Apricus Biosciences has higher revenue and earnings than Sophiris Bio. Sophiris Bio is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sophiris Bio and Apricus Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sophiris Bio N/A -85.20% -38.89%
Apricus Biosciences N/A -527.09% -126.76%

Insider & Institutional Ownership

5.5% of Sophiris Bio shares are owned by institutional investors. Comparatively, 23.4% of Apricus Biosciences shares are owned by institutional investors. 3.9% of Sophiris Bio shares are owned by company insiders. Comparatively, 3.6% of Apricus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Sophiris Bio has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Apricus Biosciences has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Sophiris Bio and Apricus Biosciences, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sophiris Bio 0 0 4 0 3.00
Apricus Biosciences 0 0 2 0 3.00

Sophiris Bio presently has a consensus target price of $6.25, suggesting a potential upside of 180.27%. Apricus Biosciences has a consensus target price of $5.00, suggesting a potential upside of 115.52%. Given Sophiris Bio’s higher possible upside, equities analysts clearly believe Sophiris Bio is more favorable than Apricus Biosciences.

Summary

Sophiris Bio beats Apricus Biosciences on 6 of the 11 factors compared between the two stocks.

Sophiris Bio Company Profile

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Apricus Biosciences Company Profile

Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply